go back

Sotrovimab Infusion, Home or Residence

Oregon rates for HCPCS M0248

Intravenous infusion, sotrovimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency

Rates data updated October 2026.

How much does Sotrovimab Infusion, Home or Residence cost?

$1,514typical facility fee

Insurers have agreed to pay about $1,514 for this service. Most negotiated rates run $1,514 to $2,512.

These are rates insurers have negotiated with providers, not the amount a patient is billed. What you owe depends on your plan's deductible and coinsurance. Based on rates published by 3 insurance carriers under federal price transparency rules.

How much rates vary

Facilitymedian $1,514 · 10th to 90th $1,230 to $3,236Professionalmedian $2,089 · 10th to 90th $2,089 to $2,089
$1K$2Kfacility $1,514professional $2,089

Distribution of negotiated rates across all payers (price axis is log-scale). Small sample; interpret with caution. Need provider-level prices or 24+ months of history? Contact us.

Rates by insurance carrier

Insurance Carrier
Pacific Source
Setting
Facility
Modifier
None
Typical Low
$1,230.27
Median
$1,513.56
Typical High
$1,513.56
Providence
Setting
Facility
Modifier
None
Typical Low
$1,949.84
Median
$1,949.84
Typical High
$1,659,586.91
Providence
Setting
Professional
Modifier
None
Typical Low
$2,089.30
Median
$2,089.30
Typical High
$2,089.30
Regence BlueShield
Setting
Facility
Modifier
None
Typical Low
$2,238.72
Median
$3,019.95
Typical High
$3,548.13

Where Oregon sits

The same service costs 8.5 times more in Illinois than in Pennsylvania. Every bar is a state, most expensive first. Touch or drag across it to read any state, then open that state for its carriers and full range.

Oregon· 6th of 30

$1,514

IL $6,026PA $708

Median negotiated rate in each state, from every insurer that publishes one. States where no insurer publishes a rate for this service are not shown.